Kazumasa Kase
Kanazawa, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Anti-MDA5 antibody-positive interstitial lung disease without prominent skin or muscle manifestations: A high-risk and potentially overlooked subgroup.
Journal: Respiratory medicine
Published: July 23, 2025
A 72-Year-Old Man With Progressive Dyspnea and Diffuse Lung Disease.
Journal: Chest
Published: January 16, 2025
The lung as a site for the generation of anti-MDA5 antibody in clinically amyopathic dermatomyositis.
Journal: Rheumatology (Oxford, England)
Published: May 24, 2024
Patients with idiopathic pulmonary fibrosis and refractory cough have traction bronchiectasis and distorted airway architecture: a retrospective case review study.
Journal: Journal of thoracic disease
Published: September 14, 2023
Comparing region of interest selection and whole-field analysis for measurement of ciliary beat frequency in high-speed video analysis.
Journal: Respiratory investigation
Published: July 13, 2023
Unexpected Diffuse Alveolar Hemorrhage After Bronchoscopy.
Journal: Chest
Published: February 22, 2023
Prognostic value of coexisting conditions and complications in pleuroparenchymal fibroelastosis: a single-center retrospective study.
Journal: Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG
Published: October 23, 2022
Long-Term Survival of Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor Monotherapy in Real-World Settings.
Journal: Clinical lung cancer
Published: November 10, 2021
Kinetic changes in serum KL-6 levels predict disease progression in patients with systemic sclerosis-associated interstitial lung disease.
Journal: Respiratory medicine
Published: September 04, 2021
Fractional analysis of bronchoalveolar lavage in systemic sclerosis-associated interstitial lung disease.
Journal: Journal of thoracic disease
Published: August 04, 2020
Emergence of lung cancer with a low PD-L1 expression level after the administration of immune check point inhibitor for lung adenocarcinoma with a high PD-L1 expression level: A case report.
Journal: Annals of medicine and surgery (2012)
Published: January 24, 2020
Real-World Efficacy of First-Line Pembrolizumab in Patients With Advanced or Recurrent Non-Small-Cell Lung Cancer and High PD-L1 Tumor Expression.
Journal: Clinical lung cancer
Published: September 14, 2019
Last Updated: 09/26/2026